REFERENCES
1. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145(6).
2. Akcabelen YM, Koca Yozgat A, Parlakay AN, Yarali N. COVID-19 in a child with severe aplastic anemia. Pediatr Blood Cancer.2020;67(8):e28443.
3. Paton C, Mathews L, Groarke EM, et al. COVID-19 infection in patients with severe aplastic anaemia. Br J Haematol. 2021.
4. Keiffer G, French Z, Wilde L, Filicko-O’Hara J, Gergis U, Binder AF. Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia. Front Oncol. 2020;10:562625.
5. Dixon L, Varley J, Gontsarova A, et al. COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia. Neurol Neuroimmunol Neuroinflamm. 2020;7(5).
6. Wang Y, Lu X, Chen T, Wang J. Lessons from a patient with severe aplastic anemia complicated with COVID-19. Asian J Surg.2021;44(1):386-388.
7. Mazzini L, Martinuzzi D, Hyseni I, et al. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. J Immunol Methods. 2021;489:112937.
8. Piccoli L, Park YJ, Tortorici MA, et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell.2020;183(4):1024-1042.e1021.
9. Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52).
10. Minotti C, Tirelli F, Barbieri E, Giaquinto C, Donà D. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. J Infect. 2020;81(1):e61-e66.
11. Filocamo G, Minoia F, Carbogno S, Costi S, Romano M, Cimaz R. Absence of Severe Complications From SARS-CoV-2 Infection in Children With Rheumatic Diseases Treated With Biologic Drugs. J Rheumatol.2020.
12. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet.2020;395(10229):1033-1034.
13. Ma H, Zeng W, He H, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020;17(7):773-775.
14. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2.Proc Natl Acad Sci U S A. 2020;117(21):11727-11734.
15. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science.2020;367(6485):1444-1448.
16. Nakano Y, Kurano M, Morita Y, et al. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan. Sci Rep. 2021;11(1):2776.